MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+4.84%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$704M
AUM Growth
+$704M
(+5.7%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
18.31%
Top 10 Holdings %
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7
Top Buys
| 1 |
Zai Lab
ZLAB
|
$21M |
| 2 |
Scholar Rock
SRRK
|
$18M |
| 3 |
PTC Therapeutics
PTCT
|
$15.6M |
| 4 |
Context Therapeutics
CNTX
|
$15.4M |
| 5 |
Replimune Group
REPL
|
$11.5M |
Top Sells
| 1 |
Insmed
INSM
|
$15.6M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$15.4M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$10.4M |
| 4 |
Viking Therapeutics
VKTX
|
$7.66M |
| 5 |
Intellia Therapeutics
NTLA
|
$5.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Twist Bioscience
TWST
$1.57B
| $12.4M | 1.76% |
267,497
-27,433
| -9% | -$1.27M |
|
27
Compass Therapeutics
CMPX
$466M
| $12.4M | 1.76% |
8,567,896
+2,926,002
| +52% | +$4.24M |
|
28
Janux Therapeutics
JANX
$1.38B
| $12.3M | 1.75% |
230,000
+58,895
| +34% | +$3.15M |
|
|
29
Replimune Group
REPL
$460M
| $11.5M | 1.63% |
+950,000
| New | +$11.5M |
|
30
Nuvation Bio
NUVB
$1.08B
| $11.1M | 1.57% |
+4,164,178
| New | +$11.1M |
|
31
Vera Therapeutics
VERA
$1.47B
| $10.9M | 1.55% |
+257,788
| New | +$10.9M |
|
32
IDEAYA Biosciences
IDYA
$2.26B
| $10.6M | 1.51% |
+414,035
| New | +$10.6M |
|
33
Relay Therapeutics
RLAY
$709M
| $9.35M | 1.33% |
2,268,825
+235,784
| +12% | +$971K |
|
34
United Therapeutics
UTHR
$17.7B
| $8.12M | 1.15% |
+23,000
| New | +$8.12M |
|
35
Arcturus Therapeutics
ARCT
$467M
| $7.81M | 1.11% |
459,943
+240,435
| +110% | +$4.08M |
|
36
Xenon Pharmaceuticals
XENE
$2.99B
| $7.73M | 1.1% |
197,212
+31,412
| +19% | +$1.23M |
|
37
Stoke Therapeutics
STOK
$1.08B
| $7.56M | 1.07% |
685,826
+206,374
| +43% | +$2.28M |
|
38
Aquestive Therapeutics
AQST
$478M
| $5.74M | 0.81% |
1,611,833
-184,917
| -10% | -$658K |
|
39
Axsome Therapeutics
AXSM
$6.09B
| $4.23M | 0.6% |
+50,000
| New | +$4.23M |
|
40
Sutro Biopharma
STRO
$85.6M
| $3.97M | 0.56% |
2,160,062
-672,002
| -24% | -$1.24M |
|
41
Werewolf Therapeutics
HOWL
$62.6M
| $3.53M | 0.5% |
2,388,011
| – | – |
|
42
Design Therapeutics
DSGN
$339M
| $3.45M | 0.49% |
+559,547
| New | +$3.45M |
|
43
Zentalis Pharmaceuticals
ZNTL
$123M
| $3.35M | 0.48% |
1,106,851
-358,950
| -24% | -$1.09M |
|
44
Veru
VERU
$48.5M
| $2.79M | 0.4% |
+4,285,365
| New | +$2.79M |
|
|
ADAP
45
Adaptimmune Therapeutics
ADAP
$13.9M
| $2.75M | 0.39% |
5,095,912
| – | – |
|
46
ALX Oncology
ALXO
$54.6M
| $2.32M | 0.33% |
1,391,434
-1,018,428
| -42% | -$1.7M |
|
47
Repare Therapeutics
RPTX
$73.9M
| $1.61M | 0.23% |
1,231,154
-408,695
| -25% | -$535K |
|
48
89bio
ETNB
$1.37B
| – | – |
-330,000
| Closed | -$2.44M |
|
|
49
KalVista Pharmaceuticals
KALV
$713M
| – | – |
-896,915
| Closed | -$10.4M |
|
|
50
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-72,395
| Closed | -$15.4M |
|